Cristin-person-ID: 393287
Person

Marta Sølvi Nyakas

  • Stilling:
    Overlege
    ved Avdeling for kreftbehandling ved Oslo universitetssykehus HF

Resultater Resultater

BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis.

Ny, Lars; Hernberg, Micaela M.; Nyakas, Marta Sølvi; Koivunen, Jussi Pekka; Oddershede, Lars; Yoon, Mie; Wang, Xuan; Guyot, Patricia; Geisler, Jürgen. 2020, Acta Oncologica. SAHLGREN, HY-HU, OYS, UIO, NOVARTIS, AHUS, OUS, FRANKRIKE, Gu, DANMARK, SVERIGEVitenskapelig oversiktsartikkel/review

Soluble AXL as a marker of disease progression and survival in melanoma.

Flem-Karlsen, Karine; Nyakas, Marta Sølvi; Farstad, Inger Nina; McFadden, Erin; Vernhoff, Patrik; Jacobsen, Kari Dolven; Flørenes, Vivi Ann; Mælandsmo, Gunhild Mari. 2020, PLOS ONE. UIT, UIO, OUSVitenskapelig artikkel

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

Larkin, James; Brown, Michael P.; Arance, Ana M.; Hauschild, Axel; Queirolo, Paola; Del Vecchio, Michele; Ascierto, Paolo A; Krajsová, Ivana; Schachter, Jacob; Neyns, Bart mfl.. 2019, European Journal of Cancer. UHT, HCB, UOA, ROCHE, UKSH, UNISA, OUS, SYDNEY, MARSDEN, MCGILL, SSN, TUMORI, AU, OEK, NKIAVL, UKvP, FNMOTOL, NHS, LAPAZ, BELGIA, UMCG, COI, SHEBAVitenskapelig artikkel

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.

Schadendorf, Dirk; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; Mandalà, Mario; Chiarion-Sileni, Vanna; Larkin, James; Nyakas, Marta Sølvi; Dutriaux, Caroline; Haydon, Andrew mfl.. 2019, The Lancet Oncology. RPA, UTA, SYDNEY, UKSH, UBORDEAUX, UdRI, LILLE1, NHS, WSLHD, UQ, MACQ, UNIVPITT, UK-ESSEN, MMH, OUS, MARSDEN, SSN, INSERM, TUMORI, IGR, NCL, NOVARTIS, DKFZ, SHEBA, USZ, INDIAVitenskapelig artikkel

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

Jansen, Yanina Jeanne Leona; Rozeman, Elisa A. Lisette; Mason, Robert; Goldinger, Simone Maria A.; Geukes Foppen, Marnix H.; Højberg, Lise; Schmidt, Henrik; van Thienen, Johannes V.; Haanen, John B.A.G.; Tiainen, Leena mfl.. 2019, Annals of Oncology. TAYS, AUSTRALIA, OUH, HCB, SYDNEY, OUS, UIB, AU, HY-HU, NKIAVL, RH, UZB, USZVitenskapelig artikkel
1 - 5 av 22 | Neste | Siste »